New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients

• Roche Holdings AG (OTC: RHHBY) announced new long-term data for Evrysdi (risdiplam) in a broad range of people aged 2-25 years with spinal muscular atrophy (SMA) from the pivotal SUNFISH study.

• Data confirm that increases in motor function were sustained at four years, and the overall rate of adverse events continued to decrease over the 48 months, reinforcing the long-term efficacy and safety of Evrysdi.

• Participants also reported continuous improvement or stabilization when independently performing activities of daily living such as eating, drinking, and picking up and moving objects.

• The increase in motor function from baseline observed during the first year of the study was maintained through the fourth year of treatment with Evrysdi.

• Without treatment, natural history data show that patients with Type 2 or 3 SMA typically show a decline in motor function over time.

• Evrysdi was well-tolerated over the four years. Adverse events (AEs) and serious adverse events (SAEs) reflected the underlying disease.

• The most commonly reported AEs include headache, fever (pyrexia), and upper respiratory tract infection.

• No treatment-related AEs led to withdrawal from the study.

• Price Action: RHHBY shares are up 0.51% at $35.25 on the last check Monday.

• Photo Via Company

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.